Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-Term Safety of MorphiDex®

Published byElfrieda Terry Modified over 5 years ago

Similar presentations

Presentation on theme: "Long-Term Safety of MorphiDex®"— Presentation transcript:

1 Long-Term Safety of MorphiDex®
Ronald Goldblum, MD  Journal of Pain and Symptom Management  Volume 19, Issue 1, Pages (January 2000) DOI: /S (99)

2 Fig. 1 The MorphiDex® exposure population shows a decreasing percentage of somnolence during 12 months of treatment Journal of Pain and Symptom Management  , 50-56DOI: ( /S (99) )

3 Fig. 2 The prevalence rate of somnolence in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (N = 278) (shaded bars) shows the change over time is due to the decrease in the incidence of somnolence, and not related to subject discontinuation during MorphiDex® therapy Journal of Pain and Symptom Management  , 50-56DOI: ( /S (99) )

4 Fig. 3 The prevalence rate of nausea in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) also shows a decrease in the incidence of nausea over time Journal of Pain and Symptom Management  , 50-56DOI: ( /S (99) )

5 Fig. 4 The prevalence rate of constipation in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows, after an initial slight decrease, the incidence of constipation is fairly constant over time Journal of Pain and Symptom Management  , 50-56DOI: ( /S (99) )

6 Fig. 5 The prevalence rate of dizziness in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows dizziness also decreases over time Journal of Pain and Symptom Management  , 50-56DOI: ( /S (99) )

7 Fig. 6 The prevalence rate of confusion in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows confusion decreases over time Journal of Pain and Symptom Management  , 50-56DOI: ( /S (99) )

8 Fig. 7 The prevalence rate of vomiting in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows the number of patients reporting vomiting declines after 3 months of therapy Journal of Pain and Symptom Management  , 50-56DOI: ( /S (99) )

Download ppt "Long-Term Safety of MorphiDex®"

Similar presentations

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.
Comparison of the Constipation Assessment Scale and Plain Abdominal Radiography in the Assessment of Constipation in Advanced Cancer Patients Kittiphon.

Comparison of the Constipation Assessment Scale and Plain Abdominal Radiography in the Assessment of Constipation in Advanced Cancer Patients Kittiphon.
Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: A Prospective Multicenter Cohort Study  Jian Chen, PhD, Xiao-yang Lu,

Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: A Prospective Multicenter Cohort Study  Jian Chen, PhD, Xiao-yang Lu,
Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation  Samuel Vokurka, MD, PhD 

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation  Samuel Vokurka, MD, PhD 
The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED  Jesse J. Sturm, MD, MPH, Harold.

The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED  Jesse J. Sturm, MD, MPH, Harold.
Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K
Wen Jing Chung, MD, MS, Gregory H. Pharo, DO 

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO 
Susan Enguidanos, PhD, MPH, Jennifer Ailshire, PhD 

Susan Enguidanos, PhD, MPH, Jennifer Ailshire, PhD 
An Assessment of the Safety, Eff icacy, and Acceptability of Intranasal Fentanyl Citrate in the Management of Cancer-Related Breakthrough Pain  Giovambattista.

An Assessment of the Safety, Eff icacy, and Acceptability of Intranasal Fentanyl Citrate in the Management of Cancer-Related Breakthrough Pain  Giovambattista.
Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients  Tatsuya Morita, MD, Junichi Tsunoda, MD, Satoshi Inoue, MD,

Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients  Tatsuya Morita, MD, Junichi Tsunoda, MD, Satoshi Inoue, MD,
Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: A Prospective Multicenter Cohort Study  Jian Chen, PhD, Xiao-yang Lu,

Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: A Prospective Multicenter Cohort Study  Jian Chen, PhD, Xiao-yang Lu,
Comparison of Tropisetron and Chlorpromazine Combinations in the Control of Nausea and Vomiting in Patients with Advanced Cancer  Kyriaki Mystakidou,

Comparison of Tropisetron and Chlorpromazine Combinations in the Control of Nausea and Vomiting in Patients with Advanced Cancer  Kyriaki Mystakidou,
Anita L Comley, PhD, RN, AOCN, Elaine DeMeyer, RN, MSN, AOCN 

Anita L Comley, PhD, RN, AOCN, Elaine DeMeyer, RN, MSN, AOCN 
Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine  Rainer Sabatowski, MD, Stefan.

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine  Rainer Sabatowski, MD, Stefan.
Rapid Progression of Advanced “Hormone-Resistant” Prostate Cancer During Palliative Treatment with Progestins for Cancer Cachexia  Davide Tassinari, MD,

Rapid Progression of Advanced “Hormone-Resistant” Prostate Cancer During Palliative Treatment with Progestins for Cancer Cachexia  Davide Tassinari, MD,
Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer  Alfredo H. Navigante, MD, PhD,

Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer  Alfredo H. Navigante, MD, PhD,
Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation  Samuel Vokurka, MD, PhD 

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation  Samuel Vokurka, MD, PhD 
Acupressure Bands Are Effective in Reducing Radiation Therapy-Related Nausea  Joseph A. Roscoe, PhD, Peter Bushunow, MD, Pascal Jean-Pierre, PhD, Charles.

Acupressure Bands Are Effective in Reducing Radiation Therapy-Related Nausea  Joseph A. Roscoe, PhD, Peter Bushunow, MD, Pascal Jean-Pierre, PhD, Charles.
Coxibs—Beyond the GI Tract

Coxibs—Beyond the GI Tract
Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course  Alexander Klaus, MD, Ronald A Hinder, MD, PhD, Kenneth.

Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course  Alexander Klaus, MD, Ronald A Hinder, MD, PhD, Kenneth.

Similar presentations

Ads by Google